ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Evidence for PSA Screening
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 203899" data-attributes="member: 13851"><p>[MEDIA=youtube]f6xOooVDxwU[/MEDIA]</p><p></p><p></p><p><strong>Screening and Prevention of Prostate Cancer 2021 (Part 1): Evidence for PSA Screening – Summary:</strong></p><p></p><p><em>In part 1 of a 3-part series, Sigrid V. Carlsson, MD, Ph.D., MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center, looks at the evidence supporting widespread prostate-specific antigen (PSA) screening. She briefly discusses the history of PSA as a marker for prostate cancer, then looks at the evidence from 3 large randomized trials on PSA with long follow-up. Dr. Carlsson explains that these studies provide compatible evidence that regular PSA screening reduces prostate cancer mortality by approximately 30%. Other studies also indicate that the balance between benefits and harms of screening improves over time, that the death rate from prostate cancer in the US declined with the rise of PSA screening, and that the US is now seeing a definitive and sustained increase in prostate cancer metastases in the US consistent with decreases in PSA screening. Dr. Carlsson then gives an overview of risk factors associated with prostate cancer incidence and mortality, including geographic location, age, family history, African ancestry, and the BRCA2 gene, all of which are incorporated into the NCCN guidelines on PSA screening. She also points out that PSA level at different points in life is also a particularly good indicator of risk, and that re-screening intervals should be adapted based on age, general health, and prior PSA. Dr. Carlsson does observe, however, that the undeniable reduction in prostate cancer mortality due to PSA screening is somewhat offset by a reduction in quality-adjusted life years, mainly as a result of the long-term side effects of treatment. She concludes by introducing her 5 Golden Rules of testing to keep the benefits and reduce the harms, all of which focus on consent and caution.</em></p><p></p><p></p><p>[ATTACH=full]15297[/ATTACH]</p><p>[ATTACH=full]15298[/ATTACH]</p><p>[ATTACH=full]15299[/ATTACH]</p><p>[ATTACH=full]15300[/ATTACH]</p></blockquote><p></p>
[QUOTE="madman, post: 203899, member: 13851"] [MEDIA=youtube]f6xOooVDxwU[/MEDIA] [B]Screening and Prevention of Prostate Cancer 2021 (Part 1): Evidence for PSA Screening – Summary:[/B] [I]In part 1 of a 3-part series, Sigrid V. Carlsson, MD, Ph.D., MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center, looks at the evidence supporting widespread prostate-specific antigen (PSA) screening. She briefly discusses the history of PSA as a marker for prostate cancer, then looks at the evidence from 3 large randomized trials on PSA with long follow-up. Dr. Carlsson explains that these studies provide compatible evidence that regular PSA screening reduces prostate cancer mortality by approximately 30%. Other studies also indicate that the balance between benefits and harms of screening improves over time, that the death rate from prostate cancer in the US declined with the rise of PSA screening, and that the US is now seeing a definitive and sustained increase in prostate cancer metastases in the US consistent with decreases in PSA screening. Dr. Carlsson then gives an overview of risk factors associated with prostate cancer incidence and mortality, including geographic location, age, family history, African ancestry, and the BRCA2 gene, all of which are incorporated into the NCCN guidelines on PSA screening. She also points out that PSA level at different points in life is also a particularly good indicator of risk, and that re-screening intervals should be adapted based on age, general health, and prior PSA. Dr. Carlsson does observe, however, that the undeniable reduction in prostate cancer mortality due to PSA screening is somewhat offset by a reduction in quality-adjusted life years, mainly as a result of the long-term side effects of treatment. She concludes by introducing her 5 Golden Rules of testing to keep the benefits and reduce the harms, all of which focus on consent and caution.[/I] [ATTACH type="full" alt="Screenshot (5765).png"]15297[/ATTACH] [ATTACH type="full" alt="Screenshot (5766).png"]15298[/ATTACH] [ATTACH type="full" alt="Screenshot (5767).png"]15299[/ATTACH] [ATTACH type="full" alt="Screenshot (5768).png"]15300[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Evidence for PSA Screening
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top